phenytoin	Propranolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	D011433
phenytoin	Propranolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	D011433
phenytoin	Propranolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	D011433
phenytoin	Propranolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	D011433
phenytoin	Propranolol	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	8787	8183	D011433
phenytoin	Propranolol	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	8787	8183	D011433
phenytoin	propranolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	8787
phenytoin	propranolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	8787
phenytoin	propranolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	8787
phenytoin	propranolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	8787	8183	8787
phenytoin	propranolol	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	8787	8183	8787
phenytoin	propranolol	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	8787	8183	8787
phenytoin	Nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	6	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	6	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	7	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	7	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	7435	8183	D015737
phenytoin	Nisoldipine	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	7435	8183	D015737
phenytoin	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	1202	8183	1202
phenytoin	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	1202	8183	1202
phenytoin	atenolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	1202	8183	1202
phenytoin	atenolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	1202	8183	1202
phenytoin	nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	6	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	6	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	nisoldipine	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	7	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	7	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	7435	8183	D015737
phenytoin	nisoldipine	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8183	7435	8183	D015737
phenytoin	histamine	5	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	5333	8183	D006632
phenytoin	histamine	5	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		8183	5333	8183	D006632
Quinidine	Propranolol	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	8787	9068	D011433
Quinidine	Propranolol	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	8787	9068	D011433
Quinidine	warfarin	11	13	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	11289	9068	D014859
Quinidine	warfarin	11	13	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	11289	9068	D014859
Quinidine	digoxin	11	13	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	3407	9068	3407
Quinidine	digoxin	11	13	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	3407	9068	3407
Quinidine	propranolol	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	8787	9068	8787
Quinidine	propranolol	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	8787	9068	8787
Quinidine	Nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	13	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	7435	9068	D015737
Quinidine	Nisoldipine	11	13	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	7435	9068	D015737
Quinidine	atenolol	10	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	1202	9068	1202
Quinidine	atenolol	10	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	1202	9068	1202
Quinidine	atenolol	11	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	1202	9068	1202
Quinidine	atenolol	11	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	1202	9068	1202
Quinidine	quinidine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	9068
Quinidine	quinidine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	9068
Quinidine	quinidine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	9068
Quinidine	quinidine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	9068
Quinidine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	13	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	7435	9068	D015737
Quinidine	nisoldipine	11	13	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	7435	9068	D015737
Ranitidine	Nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	Nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	Nisoldipine	2	2	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	Nisoldipine	2	2	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	Nisoldipine	2	4	false	none	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		9143	7435	D011899	D015737
Ranitidine	Nisoldipine	2	4	false	none	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		9143	7435	D011899	D015737
Ranitidine	cimetidine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	2541	D011899	2541
Ranitidine	cimetidine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	2541	D011899	2541
Ranitidine	nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	nisoldipine	2	2	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	nisoldipine	2	2	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		9143	7435	D011899	D015737
Ranitidine	nisoldipine	2	4	false	none	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		9143	7435	D011899	D015737
Ranitidine	nisoldipine	2	4	false	none	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		9143	7435	D011899	D015737
Ranitidine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		9143	5333	D011899	D006632
Ranitidine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		9143	5333	D011899	D006632
Propranolol	propranolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		D011433	8787
Propranolol	propranolol	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D011433	8787
Propranolol	propranolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D011433	8787
Propranolol	propranolol	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D011433	8787
Propranolol	Nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	D011433	D015737
Propranolol	Nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	D011433	D015737
Propranolol	atenolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	1202	D011433	1202
Propranolol	atenolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	1202	D011433	1202
Propranolol	atenolol	7	9	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	D011433	1202
Propranolol	atenolol	7	9	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	D011433	1202
Propranolol	atenolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	1202	D011433	1202
Propranolol	atenolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	1202	D011433	1202
Propranolol	atenolol	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	D011433	1202
Propranolol	atenolol	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	D011433	1202
Propranolol	quinidine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	9068	D011433	9068
Propranolol	quinidine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	9068	D011433	9068
Propranolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	D011433	D015737
Propranolol	nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	D011433	D015737
warfarin	digoxin	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	3407	D014859	3407
warfarin	digoxin	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	3407	D014859	3407
warfarin	Nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	Nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	Nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	Nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	quinidine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	9068	D014859	9068
warfarin	quinidine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	9068	D014859	9068
warfarin	nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
warfarin	nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		11289	7435	D014859	D015737
digoxin	Nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	Nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	Nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	Nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	quinidine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	9068	3407	9068
digoxin	quinidine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	9068	3407	9068
digoxin	nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
digoxin	nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		3407	7435	3407	D015737
propranolol	Nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	Nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	8787	D015737
propranolol	Nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	8787	D015737
propranolol	atenolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	1202	8787	1202
propranolol	atenolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	1202	8787	1202
propranolol	atenolol	7	9	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	8787	1202
propranolol	atenolol	7	9	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	8787	1202
propranolol	atenolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	1202	8787	1202
propranolol	atenolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	1202	8787	1202
propranolol	atenolol	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	8787	1202
propranolol	atenolol	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	1202	8787	1202
propranolol	quinidine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	9068	8787	9068
propranolol	quinidine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	9068	8787	9068
propranolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	nisoldipine	7	9	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	8787	D015737
propranolol	nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		8787	7435	8787	D015737
Nisoldipine	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		7435	1202	D015737	1202
Nisoldipine	atenolol	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		7435	1202	D015737	1202
Nisoldipine	atenolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		7435	1202	D015737	1202
Nisoldipine	atenolol	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		7435	1202	D015737	1202
Nisoldipine	atenolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		7435	1202	D015737	1202
Nisoldipine	atenolol	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		7435	1202	D015737	1202
Nisoldipine	atenolol	7	9	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	7	9	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		7435	1202	D015737	1202
Nisoldipine	atenolol	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		7435	1202	D015737	1202
Nisoldipine	atenolol	8	9	true	negative	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	8	9	true	negative	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	9	7	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	9	7	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	9	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	9	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		7435	1202	D015737	1202
Nisoldipine	atenolol	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	1202	D015737	1202
Nisoldipine	atenolol	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	1202	D015737	1202
Nisoldipine	atenolol	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	1202	D015737	1202
Nisoldipine	atenolol	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	1202	D015737	1202
Nisoldipine	cimetidine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  		7435	2541	D015737	2541
Nisoldipine	cimetidine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  		7435	2541	D015737	2541
Nisoldipine	cimetidine	2	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		7435	2541	D015737	2541
Nisoldipine	cimetidine	2	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		7435	2541	D015737	2541
Nisoldipine	quinidine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	9068	D015737	9068
Nisoldipine	quinidine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	9068	D015737	9068
Nisoldipine	quinidine	9	10	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	9068	D015737	9068
Nisoldipine	quinidine	9	10	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	9068	D015737	9068
Nisoldipine	quinidine	9	11	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	9	11	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	9068	D015737	9068
Nisoldipine	quinidine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		7435	9068	D015737	9068
Nisoldipine	quinidine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		7435	9068	D015737	9068
Nisoldipine	quinidine	13	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		7435	9068	D015737	9068
Nisoldipine	quinidine	13	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		7435	9068	D015737	9068
Nisoldipine	nisoldipine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  		D015737	D015737
Nisoldipine	nisoldipine	1	2	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		D015737	D015737
Nisoldipine	nisoldipine	2	1	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		D015737	D015737
Nisoldipine	nisoldipine	2	2	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		D015737	D015737
Nisoldipine	nisoldipine	2	4	false	none	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		D015737	D015737
Nisoldipine	nisoldipine	4	2	false	none	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		D015737	D015737
Nisoldipine	nisoldipine	4	4	false	none	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		D015737	D015737
Nisoldipine	nisoldipine	4	5	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		D015737	D015737
Nisoldipine	nisoldipine	4	6	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		D015737	D015737
Nisoldipine	nisoldipine	5	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		D015737	D015737
Nisoldipine	nisoldipine	5	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		D015737	D015737
Nisoldipine	nisoldipine	5	6	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		D015737	D015737
Nisoldipine	nisoldipine	5	7	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		D015737	D015737
Nisoldipine	nisoldipine	6	4	true	positive	CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		D015737	D015737
Nisoldipine	nisoldipine	6	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		D015737	D015737
Nisoldipine	nisoldipine	6	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  		D015737	D015737
Nisoldipine	nisoldipine	6	7	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		D015737	D015737
Nisoldipine	nisoldipine	6	8	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D015737	D015737
Nisoldipine	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		D015737	D015737
Nisoldipine	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		D015737	D015737
Nisoldipine	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		D015737	D015737
Nisoldipine	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D015737	D015737
Nisoldipine	nisoldipine	7	9	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		D015737	D015737
Nisoldipine	nisoldipine	8	6	true	positive	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D015737	D015737
Nisoldipine	nisoldipine	8	7	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D015737	D015737
Nisoldipine	nisoldipine	8	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		D015737	D015737
Nisoldipine	nisoldipine	8	9	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		D015737	D015737
Nisoldipine	nisoldipine	8	10	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		D015737	D015737
Nisoldipine	nisoldipine	9	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		D015737	D015737
Nisoldipine	nisoldipine	9	8	false	none	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		D015737	D015737
Nisoldipine	nisoldipine	9	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		D015737	D015737
Nisoldipine	nisoldipine	9	10	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		D015737	D015737
Nisoldipine	nisoldipine	9	11	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		D015737	D015737
Nisoldipine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		D015737	D015737
Nisoldipine	nisoldipine	10	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		D015737	D015737
Nisoldipine	nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		D015737	D015737
Nisoldipine	nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		D015737	D015737
Nisoldipine	nisoldipine	11	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		D015737	D015737
Nisoldipine	nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		D015737	D015737
Nisoldipine	nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		D015737	D015737
Nisoldipine	nisoldipine	11	13	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		D015737	D015737
Nisoldipine	nisoldipine	13	11	false	none	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		D015737	D015737
Nisoldipine	nisoldipine	13	13	false	none	No significant interactions were found between nisoldipine and warfarin or digoxin.  		D015737	D015737
Nisoldipine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
Nisoldipine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
Nisoldipine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
Nisoldipine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
Nisoldipine	histamine	4	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		7435	5333	D015737	D006632
Nisoldipine	histamine	4	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		7435	5333	D015737	D006632
Nisoldipine	histamine	5	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		7435	5333	D015737	D006632
Nisoldipine	histamine	5	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		7435	5333	D015737	D006632
atenolol	quinidine	9	10	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		1202	9068	1202	9068
atenolol	quinidine	9	10	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		1202	9068	1202	9068
atenolol	quinidine	9	11	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		1202	9068	1202	9068
atenolol	quinidine	9	11	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		1202	9068	1202	9068
atenolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	5	true	positive	Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	6	false	none	Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered.  Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	7	false	none	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	8	true	positive	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	9	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	7	9	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	7	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	7	true	negative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.  Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	8	true	negative	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	8	true	negative	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	9	false	none	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	10	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	10	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	11	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		1202	7435	1202	D015737
atenolol	nisoldipine	9	11	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		1202	7435	1202	D015737
cimetidine	nisoldipine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  		2541	7435	2541	D015737
cimetidine	nisoldipine	1	1	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  		2541	7435	2541	D015737
cimetidine	nisoldipine	1	2	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		2541	7435	2541	D015737
cimetidine	nisoldipine	1	2	true	positive	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  		2541	7435	2541	D015737
cimetidine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		2541	5333	2541	D006632
cimetidine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		2541	5333	2541	D006632
quinidine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	8	true	positive	Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.  The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	10	11	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	9	true	positive	The blood pressure effect of Nisoldipine tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.  Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	10	true	positive	Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.  Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	11	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	13	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	7435	9068	D015737
quinidine	nisoldipine	11	13	true	positive	Immediate release nisoldipine increased plasma quinidine concentrations by about 20%.  This interaction was not accompanied by ECG changes and its clinical significance is not known.  No significant interactions were found between nisoldipine and warfarin or digoxin.  		9068	7435	9068	D015737
nisoldipine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
nisoldipine	histamine	1	3	true	negative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.  Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
nisoldipine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
nisoldipine	histamine	2	3	true	negative	Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20%).  No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  		7435	5333	D015737	D006632
nisoldipine	histamine	4	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		7435	5333	D015737	D006632
nisoldipine	histamine	4	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  		7435	5333	D015737	D006632
nisoldipine	histamine	5	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		7435	5333	D015737	D006632
nisoldipine	histamine	5	3	false	none	No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.  CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general.  Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.  		7435	5333	D015737	D006632
